Lysosomal acid lipase deficiency (LAL-D) is an autosomal recessive inherited lysosomal storage disease caused by pathogenic variants in the LIPA gene. The reduced or absent activity of this enzyme prevents the proper breakdown of cholesterol esters and triglycerides, which accumulate in the liver, spleen, intestine, and other tissues.
Lysosomal acid lipase deficiency
The LIPA gene encodes lysosomal acid lipase, an enzyme present in lysosomes, the compartments responsible for recycling cellular materials. Its main function is to hydrolyze cholesterol esters and triglycerides from lipoproteins, releasing cholesterol and fatty acids for reuse. When pathogenic variants exist in LIPA, enzyme activity is markedly reduced or absent.
As a consequence, undegraded lipids progressively accumulate within lysosomes, especially in hepatocytes, macrophages, spleen, intestine, and adrenal glands. The clinical spectrum depends on the residual enzyme activity: the severe infantile form is classically known as Wolman disease, while later-onset forms are called cholesterol ester storage disease (CESD). Inheritance is autosomal recessive, meaning the disease appears when two altered copies of LIPA are inherited. Its exact prevalence is unknown, although it appears to be increased in some groups, such as the Iranian-Jewish population.
Symptoms
The age of onset and severity depend on residual enzyme activity. The severe infantile form appears in the first weeks or months of life with vomiting, diarrhea, malnutrition, growth delay, hepatosplenomegaly, and often adrenal calcification; without treatment, it can rapidly progress to multiorgan failure. Late-onset forms may manifest in infancy, adolescence, or adulthood with hepatomegaly, hepatic steatosis, persistent elevation of transaminases, dyslipidemia with elevated LDL cholesterol, and an increased risk of atherosclerosis and premature cardiovascular disease. In stages, fibrosis, cirrhosis, and liver failure may appear.
Disease management
Management is based on early diagnosis and treatment, hepatic and cardiometabolic monitoring, and complication prevention. Enzyme replacement therapy with sebelipase alfa, administered intravenously, provides a recombinant form of LAL and can improve survival in the infantile form and hepatic and lipid parameters in later-onset forms. Additionally, nutritional support, fat restriction under specialized supervision, and dyslipidemia treatment with statins or other drugs may be required, although these do not correct the lysosomal defect. In cases, specific supportive measures may be necessary, including assessment for liver transplantation.
Genes analyzed
Bibliography
Hoffman EP, Barr ML, Giovanni MA, et al. Lysosomal Acid Lipase Deficiency. 2015 Jul 30 [updated 2016 Sep 1]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Valles-Ayoub Y, Esfandiarifard S, No D, et al. Wolman disease (LIPA p.G87V) genotype frequency in people of Iranian-Jewish ancestry. Genet Test Mol Biomarkers. 2011 Jun;15(6):395-8.
